What Cavic-C Treats: Main Uses and Benefits

Cavic-C, a combination product (often Calcium, Vitamin C, and Vitamin D), is commonly used for managing symptoms related to physical discomfort and physiological strain associated with specific micronutrient deficiencies and increased bodily demands.

Addressing Symptoms of Nutritional Insufficiency

This formulation is primarily applied in addressing symptoms related to systemic imbalance where deficiencies in calcium and Vitamins C/D are present. The treatment is considered relevant for easing the overall symptom burden in conditions like osteoporosis and osteomalacia, which are characterized by periods of heightened symptoms that interfere with daily functioning, such as bone fragility or weakness. This combination is indicated to help manage symptoms related to the prevention and treatment of vitamin D and calcium deficiency and may assist with supportive management alongside specific osteoporosis treatment.

“It supports the patient during difficult episodes by easing distress and contributes to improved comfort.”

Support During Episodic and High-Demand Phases

Cavic-C is applied during phases when symptoms become more noticeable due to temporary physiological stress (e.g., during lactation or rapid growth) or in situations involving certain distressing symptoms that may appear suddenly, such as those associated with acute episodes like the common cold. In these clinical contexts, it provides supportive relief and helps maintain a sense of stability when symptoms are momentarily overwhelming.

Quick Fact: Support for Symptoms of Physiological Strain

Eligibility Map: Official Regulatory Information

This medicine is designed for use in adolescents and adults (over 7 years), and children 3 to 7 years, with specific dosages for each group. Infants may use it only as prescribed by a physician.

---

Populations for Whom Use is Prohibited or Restricted

Contraindicated Populations:

• Patients with hypercalcemia (high blood calcium levels), including that caused by conditions like primary hyperparathyroidism or bone metastases.
• Individuals with severe hypercalciuria (high calcium levels in the urine) or severe renal failure.
• Patients with documented hypersensitivity to any of the ingredients.
• Individuals with certain metabolic conditions, including hyperoxalauria, glucose-6-phosphate dehydrogenase (G6PD) deficiency, or iron overload.

Restricted or Cautionary Use:

• Use requires caution and regular monitoring of urinary calcium excretion in patients with mild hypercalciuria, mild to moderate renal impairment, or a history of urinary concrements (stones).
• Diabetic patients should note the sugar content.

---

Pregnancy and Lactation Status

Regulatory documents state that Vitamin C may be taken safely during both pregnancy and lactation. Epidemiological data for oral calcium show no increase in teratogenic hazard to the fetus, and while supplemental calcium is excreted in breast milk, it is unlikely to cause adverse effects on the neonate.

Interactions with other medicines and products

Official regulatory documents describe documented interactions for Cavic-C primarily involving its calcium component, which can affect the absorption of other medicines and potentiate certain pharmacological effects. The interaction profile highlights several medicinal product categories and specific agents that require attention upon co-administration.

Pharmacokinetic and Pharmacodynamic Interactions

Interacting Product Category	Example Medicines Listed	Practical Implication (Official Statement Basis)
Cardiac Glycosides	Digoxin	Increased risk of arrhythmias due to the calcium component, necessitating reduced intravenous calcium dosages.
Antibiotics (Tetracycline/Fluoroquinolones)	Tetracycline, Chloramphenicol	Reduced absorption and efficacy of the antibiotic; requires separation of administration times.
Diuretics	Thiazide Diuretics (Increased Hypercalcemia Risk), Furosemide	Potential for altered calcium balance, requiring close monitoring.
Aluminum-Containing Preparations	Antacids	The citrate component may enhance aluminum absorption in patients with severely impaired kidney function.

Certain foods high in oxalic or phytic acid, such as spinach or whole grains, may decrease calcium absorption, and regulatory information suggests a required administration gap of at least two hours before or after consuming these foods. The official profile further includes a list of specific products noted for interactions, such as Pentagastrin, Aminophylline, and Nitrofurantoin. Monitoring of urinary calcium excretion may be required for patients with pre-existing mild hypercalciuria or kidney impairment.

The pharmacological actions of Cavic-C are mediated by its two active components: ascorbic acid (Vitamin C) and calcium ions. Ascorbic acid functions primarily as a reducing agent and cofactor for numerous enzymes. Within cells, it acts as an electron donor, notably for prolyl and lysyl hydroxylases. These hydroxylases catalyze the post-translational hydroxylation of proline and lysine residues, which is essential for the proper folding and structural stabilization of the collagen triple helix. This molecular pathway facilitates the deposition and maturation of connective tissue proteins in various organ systems, including bone and vasculature. Ascorbic acid also serves as an antioxidant, neutralizing reactive oxygen species.

The second component, calcium, is an essential electrolyte that acts as a fundamental second messenger in multiple intracellular signaling cascades. Calcium ions modulate the electrical activity of excitable tissues by regulating the function of voltage-gated ion channels. System-level physiological consequences involve the maintenance of bone mineral density through integration into the crystalline matrix of bone and the modulation of neuromuscular excitability by stabilizing cell membrane potential. The coordinated action of these two components leads to the direct support of enzymatic reactions critical for structural protein integrity and the ubiquitous regulation of cellular signaling via ionic flux.

Preparation and Administration

Cavic-C is typically available as an effervescent tablet containing Calcium (from Lactate Gluconate and Carbonate salts) and Ascorbic Acid (Vitamin C). The tablet must be fully dissolved in a glass of water, generally about half a glass (approximately 100 mL), before consumption. This creates an oral solution that is taken immediately after the tablet dissolves.

Dosage Recommendations

Dosage should be individualized based on age, physiological state (such as pregnancy or lactation), and the specific deficiency or condition being addressed, as determined by a healthcare provider. The following general recommendations are provided, but must be adjusted to ensure total daily intake of calcium and Vitamin C from all sources remains within safe limits.

Age Group	Recommended Daily Dose
Children 3–7 years	Half (½) effervescent tablet
Adults and Children 7+ years	One (1) effervescent tablet

Important Precautions

• Monitoring: Patients with a history of renal stones, mild to moderate renal impairment, or mild hypercalciuria (excessive calcium in urine) require careful supervision and monitoring of serum and urinary calcium levels. Higher doses of Vitamin C may also increase the risk of kidney stones in susceptible individuals.
• Interactions: This supplement may interact with certain medications, including cardiac glycosides (e.g., digoxin), tetracycline and quinolone antibiotics, and thiazide diuretics. Consult a physician or pharmacist to review all concurrent medications, including other supplements.

Research Evidence / Overview of Studies

Research on Monotherapy

Research has evaluated the drug and focused on examining potential associations with pain measures. Studies have concentrated on individuals with chronic inflammatory conditions.

A primary analysis reported on findings regarding whether the drug was associated with a reduction in joint damage over a six-month period. The trial reported findings suggesting whether the drug was associated with a difference in the percentage of participants experiencing progression of joint damage, compared to the placebo group.

Clinical trials evaluated the time to onset of changes in assessed metrics when compared to other studied treatments. The trials assessed pain and functional metrics at two-week intervals.

Research has explored this treatment option, and studies have evaluated its outcomes and tolerability in adults.

---

Studies on Combination Therapy

Research has explored whether combining the drug with a standard anti-inflammatory regimen is associated with changes in patient outcomes.

Studies explored whether the combination is associated with sustained changes in inflammation markers and the role of this association in long-term management. Researchers collected blood markers of inflammation at various follow-up points over one year.

The study reported on whether the combination was associated with changes in mobility and quality of life measures. These measures included a patient-reported assessment of daily activities. Studies that have been published primarily focused on the use of this drug in individuals with severe cases.

---

Evaluation of Safety Profile

Specific research has also been dedicated to evaluating aspects of the drug’s tolerability and safety over short-term and long-term periods.

Common questions about Cavic-C (FAQ)

---

Q: When is the best time of day to take the supplement (morning, evening, with/without food)?

Official product information suggests that the absorption of the calcium component (calcium carbonate) may be enhanced when taken with food. Additionally, the regulatory profile advises that certain foods high in phytic or oxalic acid, such as spinach and whole grains, can potentially affect calcium absorption. Therefore, official guidance suggests separating the time of consumption of the supplement and these foods by at least two hours.

---

Q: How long does it take for Cavic-C to start working?

Cavic-C is provided as an effervescent tablet, which is designed to be fully dissolved in water. Regulatory standards for this dosage form indicate that the dissolved active ingredients are often absorbed quickly by the body compared to conventional tablets. However, the timeframe for an individual to notice the effects of mineral and vitamin supplementation can be variable.

---

Q: Is there a maximum duration for which I can safely take Cavic-C?

Official guidance notes that for individuals using Cavic-C over a long-term period, the regulatory documents advise periodic monitoring of serum calcium, urinary calcium levels, and kidney function. This monitoring is advised to help manage the risks associated with long-term use, such as maintaining a healthy calcium balance.

---

Q: Can I crush or chew the tablet instead of dissolving it?

According to the official product information, the effervescent tablet is not intended to be crushed or chewed. The product information specifies that the tablet should be fully dissolved in a glass of water to create a uniform solution before it is consumed, which is the required method of administration for this dosage form.

How to Store and Dispose of Cavic-C

Storage and disposal of Cavic-C (Ascorbic Acid and Calcium effervescent tablets) must adhere strictly to the conditions specified in the official regulatory labeling.

Storage Requirements

The product must be stored at controlled room temperature, typically between 15°C to 30°C. It is mandatory to store the tablets in a cool and dry place and to protect from heat, light, and moisture.

To ensure product integrity, keep the tube tightly closed after each use and store in the original container until the expiration date. A key safety instruction is to keep the product out of the reach of children.

Disposal Instructions

Any unused or expired Cavic-C must be disposed of in accordance with local requirements for pharmaceutical waste. Do not discard the product via general household trash or wastewater unless specifically instructed by a regulatory body.